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SUMMARY
Objective: To present a prenatal diagnosis of congenital cytomegalovirus (CMV) infection in a pregnancy with
fetal ascites.
Case Report: A 33-year-old, gravida 6, para 2, woman was referred to a hospital at 20 weeks of gestation for
management of fetal ascites. The woman had not experienced recent rubella or herpes simplex infections. The
maternal blood group was O and Rh(D)-positive. The maternal serum thalassemia and syphilis screen results
were negative. Fetal ascites was first noted at 17 weeks of gestation. At 18 weeks, she underwent amniocentesis
revealing a 46,XX karyotype. At 20 weeks of gestation, maternal serum CMV IgG and CMV IgM were positive. At
21 gestational weeks, prenatal ultrasound showed fetal ascites, hyperechogenic bowel, ventriculomegaly, and
intrauterine growth restriction. Repeated amniocentesis showed CMV DNA levels of 9.72 × 105 copies/mL and
6.03 × 105 copies/mL in amniocytes and amniotic fluid supernatant, respectively. Paracentesis showed CMV
DNA levels of 1.64 × 103 copies/mL and 114 copies/mL in ascitic cells and ascitic supernatant, respectively. The
pregnancy was terminated. Postnatally, CMV DNA was detected in the umbilical cord, amnion, placenta, cord
blood, lungs, liver and brain by quantitative real-time polymerase chain reaction.
Conclusion: A prenatal diagnosis of fetal ascites in association with ventriculomegaly, hyperechogenic bowel
and intrauterine growth restriction should alert physicians to congenital CMV infection in addition to aneu-
ploidy. The present case provides evidence that CMV DNA levels are higher in amniotic fluid (amniocytes and
amniotic fluid supernatant) than in ascites (ascitic cells and ascitic supernatant) in cases of congenital CMV
infection. [Taiwan J Obstet Gynecol 2010;49(2):206–210]
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Introduction
Cytomegalovirus (CMV) is the most common cause of
intrauterine infection in developed countries, occur-
ring in 0.2–2% of live births [1]. CMV is transmitted by
person-to-person contact via oropharyngeal secre-
tions, urine, semen, milk, tears, blood, as well as cervical
and vaginal secretions. Maternal CMV infection may
hematogenously spread the virus to the fetus through
the placenta courtesy of infected leukocytes [2]. Primary
maternal infection of CMV has a much greater clinical
impact than non-primary infection. CMV infection in
adults is usually subclinical, although clinical symptoms
are more often present in primary than non-primary
infections. In a study to compare the clinical manifes-
tations between primary infections and recurrent or non-
active infection of CMV in adults, Nigro et al [3]
observed fever in 42.1% versus 17.1%, asthenia in 31.4%
versus 11.4%, myalgia in 21.5% versus 6.7%, rhino-
pharyngo-tracheo-bronchitis in 42.1% versus 29.5%,
flu-like syndrome in 24.5% versus 9.5%, lymphocytosis
in 39.2% versus 5.7% and increased aminotransferases in
35.3% versus 3.9%. In primary maternal infections,
transmission to the fetus occurs in 30–40% of cases,
whereas with recurrent infection or re-infection, the
risk is 0.15–1% [1,4–6].
About 90% of infected fetuses are asymptomatic at
birth, and 10% of the infected fetuses are symptomatic
with characteristic clinical manifestations and compli-
cations such as low birth weight, jaundice, hepato-
splenomegaly, microcephaly, intracranial calcification,
thrombocytopenic purpura, chorioretinitis, mental and
motor retardation, sensorineural deficits and hemo-
lytic anemia, sometimes resulting in death [4,7,8].
About 10–15% of the asymptomatic infected fetuses
may develop long-term sequelae such as sensorineural
hearing loss, mental retardation, chorioretinitis, intel-
lectual deficits, and microcephaly. IgG avidity assays
are useful for distinguishing primary CMV from non-
primary CMV infections. After primary infection, the
antibody response matures from low to high avidity
antibody production, and high CMV IgG avidity is a
reliable indicator of past infection in pregnant women
with a positive IgM response [9–15]. Recently, Lagrou
et al [15] reported that the new Architect CMV IgG
avidity test (Abbott Laboratories, Abbott Park, IL,
USA) had excellent specificity (98%) in excluding
patients with recent infections. Prenatal diagnosis of
fetal ascites in association with hyperechogenic bowel,
ventriculomegaly and intrauterine growth restriction
(IUGR) should alert physicians to congenital CMV
infection in addition to aneuploidy. Here, we present
such a case.
Case Report
A 33-year-old, gravida 6, para 2, woman was referred to a
hospital at 20 gestational weeks for management of fetal
ascites. The parents were non-consanguineous and
healthy. The mother denied any recent rubella or herpes
simplex infections but had experienced three abor-
tions. There was no family history of congenital mal-
formations. The maternal blood group was O and
Rh(D)-positive. The maternal serum thalassemia and
syphilis screen results were negative. The pregnancy
was uneventful until 17 gestational weeks when fetal
ascites was noted by routine ultrasonographic exami-
nation. She underwent amniocentesis at 18 gestational
weeks because of fetal ascites. The karyotype was
46,XX. Maternal serum toxoplasmosis IgG and IgM
were negative, and maternal serum CMV IgG and CMV
IgM were positive at 20 gestational weeks. The CMV
IgG level was 904.8 AU/mL (normal, < 15 AU/mL) and
CMV IgM level was 0.56 (normal, < 0.4). The IgG avid-
ity assay revealed low CMV IgG avidity, indicative of
primary CMV infection. Level II ultrasound examination
at 21 gestational weeks revealed fetal ascites, hypere-
chogenic bowel, ventriculomegaly and IUGR (Figure 1).
The amniotic fluid index was normal. Repeat amnio-
centesis and paracentesis were performed at 21 gesta-
tional weeks. CMV DNA was detected in the samples
of ascites and amniotic fluid by quantitative real-time
polymerase chain reaction (qRT-PCR) [16]. A compari-
son of the CMV DNA levels among amniocytes, amniotic
fluid supernatant, ascitic cells and ascitic supernatant by
qRT-PCR showed that amniocytes contained the highest
levels of CMV DNA (9.72 × 105 copies/mL) followed
by the levels in the amniotic fluid supernatant (6.03 ×
105 copies/mL), ascitic cells (1.64 × 103 copies/mL)
and ascitic supernatant (114 copies/mL). There was 
a negative molecular diagnosis for parvovirus B19,
rubella, herpes simplex, and toxoplasmosis. The par-
ents opted to terminate the pregnancy. At 22 weeks of
gestation, a 526-g female fetus was delivered with a
distended abdomen and massive ascites (Figure 2). CMV
DNA was detected in the umbilical cord, amnion, pla-
centa, cord blood, lungs, liver and brain by qRT-PCR
(Figure 3).
Discussion
The present case was associated with fetal ascites, 
ventriculomegaly, hyperechogenic bowel and IUGR 
by prenatal ultrasound. In a meta-analysis of ultrasound
abnormalities in 277 pregnancies with congenital CMV
infection, Benoist and Ville [17] found that the common
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Figure 1. Prenatal ultrasound at 21 weeks of gestation showing (A) fetal ascites with hyperechogenic bowel and (B) 
ventriculomegaly.
ultrasound abnormalities were IUGR (16.2%), brain
structural abnormalities (13%), hyperechogenic bowel
(13%), ventriculomegaly (12.6%), microcephaly (9%),
ascites (7.2%), oligohydramnios/anhydramnios (5.4%),
hydrocephalus (4.7%), hydrops fetalis (2.9%), placen-
tomegaly (1.8%), polyhydramnios (1.4%), pericardial
effusion (1.4%), and pleural effusion, skin edema and
liver calcifications (< 1%). The overall detection rate of
ultrasound abnormalities in pregnancies with congeni-
tal CMV infection was 41.9% (116 of 277) as compiled
from previously published data [5,18–23].
Chen et al [24] previously reported detection of
CMV DNA in fetal ascites in a fetus at 21 weeks of ges-
tation. Fetal ascites can be an alternative source for
prenatal diagnosis of CMV infection, especially when
severe oligohydramnios or anhydramnios is present.
This report shows that CMV DNA levels are higher in
Figure 2. The fetus at birth.
amniotic fluid (amniocytes and amniotic fluid super-
natant) compared with ascites (ascitic cells and ascitic
supernatant), suggesting that amniotic fluid is more
useful than ascites in the prenatal diagnosis of fetal
CMV infection. Liesnard et al [5] reported a global
sensitivity for prenatal diagnosis of 80% and a specificity
of 100% in CMV DNA testing on amniotic fluid after
21 gestational weeks, and a 7-week interval between
diagnosis of maternal infection and amniocentesis.
However, Donner et al [25] reported 45.4% sensitivity
for CMV DNA testing on amniotic fluid before 21 ges-
tational weeks. Amniocentesis performed too soon
after the diagnosis of maternal CMV infection and a
low copy number of virus in the amniotic fluid are res-
ponsible for the lack of sensitivity of CMV DNA testing
in amniotic fluid before 21 weeks of gestation [25]. The
renal tubular epithelium is a major site of CMV repli-
cation. The infected fetus excretes CMV in the urine,
and CMV DNA is accumulated in the amniotic fluid. It
takes around 6–8 weeks from maternal seroconversion
or reactivation to excrete CMV in fetal urine [25,26].
Therefore, the CMV DNA level in amniotic fluid sam-
ples correlates with the gestational age at the time of
amniocentesis [21]. The present case provides evi-
dence that CMV DNA levels are higher in amniocytes
than in amniotic fluid supernatant and higher in ascitic
cells than in ascitic supernatant, suggesting that amnio-
cytes and ascitic cells may be useful for CMV DNA test-
ing in addition to cytogenetic analysis in the case of
fetal ascites. Prenatal diagnosis of ventriculomegaly,
hyperechogenic bowel, fetal ascites and IUGR may
lead obstetricians to suspect fetal chromosomal
abnormalities. A normal karyotype, such as that seen
in this case, should alert physicians to congenital CMV
infection.
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Figure 3. Polymerase chain reaction products of cytomegalovirus in fetal and extraembryonic tissues subjected to elec-
trophoresis on a 2% agarose gel. Lane 1: molecular weight standard; lane 2: negative control; lane 3: positive control; lanes
4–14: amplicons using DNA extracted from amniotic fluid supernatant, ascitic supernatant, amniocytes, ascitic cells, cord
blood, cord, placenta, lungs, liver, brain and amnion, respectively.
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